Michael Devitt

Assistant Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
1335 Lee St
Charlottesville, Virginia 22903
An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)
Source: Syneos Health, LLC
May 29, 2020 – May 28, 2023
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
Source: Prostate Cancer Clinical Trials Consortium, LLC
May 19, 2020 – May 18, 2023
4B-15-11: A Phase II trial of sEphB4-HSA in combination with Anti PD1 Antibody Pembrolizumab (MK-3475) for metastatic urothelial cancer refractory to platinum
Source: University of Southern California
November 19, 2019 – November 18, 2022
A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer : Targeting Resistant prostate cancer with ATR and PARP inhibition (TRAP trial)
Source: Board of Regents of the University of Michigan
September 20, 2019 – September 19, 2022
Enrollment in Prostate Cancer Trials Requiring Genomic Targets
Source: The V Foundation for Cancer Research
October 01, 2019 – January 01, 2021